bevacizumab at initiation (C4); first constraint engaged, addressing sub-threshold loading
bevacizumab (vegf blockade clearing supply line) acts at the initiation (C4); first constraint engaged step of the cancer-immunity cycle. The failure mode is sub-threshold loading: loading current never raises charge to threshold. Capacitor never fires; Activation barrier permanently inert.
What this is
The Living Scorecard is Encounter's open record of structural predictions. Each hypothesis names a candidate intervention, where in the cycle it is predicted to act, the failure mode it is predicted to address, and the evidence available when the prediction was made.
Predictions are locked with timestamps before they can be tested. Encounter generates them daily, many more than any one person can chase, so the field can see what the framework claims structurally, ahead of the data. Some will hold. Some will be refuted. Both stay on the page. The point is that each prediction is committed before the answer is known, so the data that arrives later can confirm or refute it.
Structural argument
At the initiation (C4); first constraint engaged step of the cancer-immunity cycle (factory regime, position P5), bevacizumab acts via vegf blockade clearing supply line. The failure mode is sub-threshold loading: loading current never raises charge to threshold. Capacitor never fires; Activation barrier permanently inert. The intervention's regime-type class lines up with the position's regime, and failure_sub_threshold_loading belongs to that regime's failure set.
rule_r13(required) — Combinatorial candidate is grounded in R13's position-to-state table, which determines which interventions are structurally addressable at which positions.
Substrate
- Domain
- domain_cellular_biology
- Cycle
- cycle_l4_canonical
- Position(s)
- position_p5
- Failure modes
- failure_sub_threshold_loading
Evidence at generation
"bevacizumab" AND "cancer immunotherapy"
- PMID 32335505
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
- PMID 38424197
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.
- PMID 21355777
Cancer immunotherapy.
- PMID 30119083
Combinations of Bevacizumab With Cancer Immunotherapy.
- PMID 37726418
Biomarkers for immunotherapy of hepatocellular carcinoma.
Targets: CHEMBL1783
inhibitor
bevacizumab cancer immunotherapy
- NCT04973293
Lung Neoplasm Malignant
Primary: Safety (Rate of grade 3 and higher grade treatment-related adverse events)
- NCT05158621
Metastatic Colorectal Cancer
Primary: Primary
- NCT05314101
Immunotherapy
Primary: progression free survival
- NCT04895137
Colorectal Cancer
Primary: PCR rate
- NCT05400902
Intrahepatic Cholangiocarcinoma
Primary: Response Rate
Status timeline
- Draft2026-05-30T11:27:14Z
Generated by combinatorial walker (v0.1.1; verb_target-aware, sub-regime failures). Awaiting operator review for the daily top-5 batch.
by system